119th Congress · introduced in the House · Feb 18, 2025
Cameron’s Law
Official title from Congress.gov
Latest action (Feb 18, 2025): Referred to the House Committee on Ways and Means.
View on Congress.govPolicy area: Taxation
Congressional Research Service summary, version: Introduced in House (Feb 18, 2025)
Cameron's Law
This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions.
As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Ways and Means.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
90 citations; showing the 25 most recently posted.
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
…--Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Opioid Crisis ---Coverage and Reimbursement Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.6166: Lowering Drug Costs for American Families Act ---H.R.10359: Priority for Pediatric Cures Act ---Implementation of the Inflation Red…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Taxation/Internal Revenue Code
$2,560,000
Spent on own lobbying
…s for Specific Issues ---Vaccines and Infectious Diseases ---VICP/CICP Capital Formation Incentives ---Net Operating Loss Advance Refunds Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.10359: Priority for Pediatric Cures Act Pandemic Preparedness Research & Development Tax Credit Reforms ---H.R.1: One Big Beautiful Bill…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMARIN PHARMACEUTICAL INC. · lobbying firm or registrant: BIOMARIN PHARMACEUTICAL INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$200,000
Spent on own lobbying
H.R. 1414: CAMERON'S LAW; ALL PROVISIONS
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PTC THERAPEUTICS, INC. · lobbying firm or registrant: PTC THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$170,000
Spent on own lobbying
…ion 174 R&D Amortization, including H.R. 1990 - American Innovation and R&D Competitiveness Act of 2025 Issues related to the Orphan Drug Tax Credit, including H.R. 1414 - Camerons Law
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$80,000
Paid to lobbying firm
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADIA PHARMACEUTICALS · lobbying firm or registrant: ACADIA PHARMACEUTICALS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$440,000
Spent on own lobbying
…ation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ACADIA PHARMACEUTICALS · lobbying firm or registrant: ACADIA PHARMACEUTICALS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$440,000
Spent on own lobbying
Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: TRAVERE THERAPEUTICS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$100,000
Spent on own lobbying
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutica…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: VERTEX PHARMACEUTICALS INCORPORATED
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Taxation/Internal Revenue Code
$1,100,000
Spent on own lobbying
Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) · lobbying firm or registrant: RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$60,000
Spent on own lobbying
…n Act of 2025; FY 2027 Appropriations; FDA user fee reauthorization; H.R. 7118 - Genomic Answers for Children's Health Act; H.R. 5509, S. 2903 - Safe Step Act; H.R. 1414 - Cameron's Law; H.R. 10359 - Priority for Pediatric Cures Act
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
RARE DISEASE COMPANY COALITION · lobbying firm or registrant: RARE DISEASE COMPANY COALITION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Pharmacy
$80,000
Spent on own lobbying
…EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
IONIS PHARMACEUTICALS, INC. · lobbying firm or registrant: IONIS PHARMACEUTICALS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Taxation/Internal Revenue Code
$150,000
Spent on own lobbying
Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MODERNATX, INC. · lobbying firm or registrant: THE WASHINGTON TAX & PUBLIC POLICY GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Taxation/Internal Revenue Code
$30,000
Paid to lobbying firm
…2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to IRC sections 11, 41, 45C, 951A, and 250. (H.R. 1414).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HARMONY BIOSCIENCES · lobbying firm or registrant: HARMONY BIOSCIENCES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 8, 2026 · issue area: Pharmacy
$180,000
Spent on own lobbying
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to pro…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEALTHCARE INSTITUTE OF NEW JERSEY · lobbying firm or registrant: HEALTHCARE INSTITUTE OF NEW JERSEY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 7, 2026 · issue area: Health Issues
$49,416
Spent on own lobbying
…de and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient A…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Health Issues
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Medicare/Medicaid
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Insurance
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Economics/Economic Development
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Pharmacy
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Trade (domestic/foreign)
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 29, 2026 · issue area: Financial Institutions/Investments/Securities
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Taxation/Internal Revenue Code
$70,000
Paid to lobbying firm
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLENO THERAPEUTICS, INC. · lobbying firm or registrant: SOLENO THERAPEUTICS, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Trade (domestic/foreign)
$70,000
Spent on own lobbying
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing